# Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

> **NCT06582277** · PHASE2 · COMPLETED · sponsor: **Osivax** · enrollment: 117 (actual)

## Conditions studied

- Vaccine-Preventable Diseases
- Influenza

## Interventions

- **BIOLOGICAL:** OVX836 shot

## Key facts

- **NCT ID:** NCT06582277
- **Lead sponsor:** Osivax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-10-22
- **Primary completion:** 2025-06-02
- **Final completion:** 2025-06-02
- **Target enrollment:** 117 (ACTUAL)
- **Last updated:** 2025-06-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06582277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06582277, "Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06582277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*